Targeting Cancer with CRISPR/Cas9-Based Therapy

Katarzyna Balon*, Adam Sheriff, Joanna Jacków, Łukasz Łaczmański

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

15 Citations (Scopus)

Abstract

Cancer is a devastating condition characterised by the uncontrolled division of cells with many forms remaining resistant to current treatment. A hallmark of cancer is the gradual accumulation of somatic mutations which drive tumorigenesis in cancerous cells, creating a mutation landscape distinctive to a cancer type, an individual patient or even a single tumour lesion. Gene editing with CRISPR/Cas9-based tools now enables the precise and permanent targeting of mutations and offers an opportunity to harness this technology to target oncogenic mutations. However, the development of safe and effective gene editing therapies for cancer relies on careful design to spare normal cells and avoid introducing other mutations. This article aims to describe recent advancements in cancer-selective treatments based on the CRISPR/Cas9 system, especially focusing on strategies for targeted delivery of the CRISPR/Cas9 machinery to affected cells, controlling Cas9 expression in tissues of interest and disrupting cancer-specific genes to result in selective death of malignant cells.

Original languageEnglish
Article number573
JournalInternational Journal of Molecular Sciences
Volume23
Issue number1
Early online date5 Jan 2022
DOIs
Publication statusPublished - 5 Jan 2022

Keywords

  • Cancer
  • CRISPR/Cas9
  • Genetic therapy
  • Targeting

Fingerprint

Dive into the research topics of 'Targeting Cancer with CRISPR/Cas9-Based Therapy'. Together they form a unique fingerprint.

Cite this